Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Abstract Text:

Christina ,Marie Svensson,Wenhua Wang,Ulla ,Peter Daneryd,Ola Nilsson,Kent Lundholm,Christina ,Marie Svensson,Wenhua Wang,Ulla ,Peter Daneryd,Ola Nilsson,Kent Lundholm,

Background Recombinant erythropoietin (rhEPOalpha) corrects anaemia, improves physical functioning and quality of life in cancer patients. However, published reports have suggested risks for tumour stimulation by provision EPO to patients with remaining tumour cells perhaps related to the presence of EPO receptor protein in tumour tissue. Therefore, the aim of the present study was to exclude a possibility that cancer patients who respond favourably to EPO treatment have mainly tumours with low EPO receptor protein expression. Methods Tumour tissue was evaluated in 87 patients out of 108 randomly allocated for treatment with rhEPOalpha (n = 50) versus controls (n = 58). Tumour cell proliferation (Ki-67 index) and EPO receptor protein expression were evaluated by immunohistochemistry. Results EPO treatment varied between 2 and 35 months, in doses between 10 000 and 40 000 Units/week. Ki-67 index did not differ between study and control patients before EPO treatment. Tumour tissue erythropoietin receptor protein was also similar between treated and untreated patients. Around 40% of tumour cells contained EPO receptors. Survival did not differ among EPO treated and control patients analysed as intention to treat, while survival was significantly improved in EPO treated patients per protocol treatment (P < 0.05). Ki-67 index and tumour tissue erythropoietin receptor protein did not predict survival, which systemic inflammation (ESR) did (P < 0.02). Conclusions Our results support that reported risk to accelerate disease progression by EPO treatment in palliative care is not justified in patients with solid, gastrointestinal cancer despite tumour presence of EPO receptor protein.

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Publishing Authors By Initials

C ,M Svensson,W Wang,U ,P Daneryd,O Nilsson,K Lundholm,C ,M Svensson,W Wang,U ,P Daneryd,O Nilsson,K Lundholm,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Medical oncology (Northwood, London, England)

VOLUME: 25

Page Numbers: 22-9

Journal Abbreviation: Med. Oncol.

ISSN: 1357-0560

DAY: 11

MONTH: 09

YEAR: 2007

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9435512

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

AFFILIATION: Department of Surgery, Surgical Metabolic Research Laboratory at Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Göteborg University, 413 45, Göteborg, Sweden, kent.lundholm@surgery.gu.se.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care Related Publications

• Bacterial contamination of cotton and cotton dust and effects on the lung.
• Culture of tubercle bacilli from specimens of gastric juice.
• Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia.
• Endotoxin levels in farming: absence of symptoms despite high exposure levels.
• Exposure to nitrous oxide in delivery suites at six Swedish hospitals.
• Fractures around the neck of the femur.
• Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content.
• Initiation factors for translation of proteins in the rectus abdominis muscle from patients on overnight standard parenteral nutrition before surgery.
• Interactions of cytokines in the host.
• Internal fixation of hip fractures with a new lag screw.
• Isolation of radiopure plasma and hepatic albumin in acute phase conditions.
• Nutritional problems in trauma.
• Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.
• Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.
• The effect of DFP on respiration, blood pressure and muscular function in the rabbit.
• The mechanism of the vasodilator effect of adrenaline. I. Effect on skeletal muscle vessels.
• [Not Available.]
• [Not Available.]